From BBC Health - April 18, 2006 23:01
A form of insulin that can be inhaled by diabetes sufferers is rejected by NHS advisers on grounds of cost.
Ad Statistics
Times Displayed: 51109
Times Visited: 1485 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Insulin that can be inhaled rather than injected has been rejected by NHS advisers on grounds of cost.
The drug, Exubera, is designed to offer adults with diabetes an alternative to their daily insulin injections.
Exubera for Type 1 and 2 diabetes costs £1,100 per person per year but patients would still need injections at night.
Campaigners said the draft guidance by the watchdog the National Institute for Health and Clinical Excellence for England and Wales was disappointing.
The inhaled insulin is the first non-injected option for insulin therapy since the discovery of the treatment for diabetes in the 1920s.
